Brown, Jennifer R. http://orcid.org/0000-0003-2040-4961
Zelenetz, Andrew
Furman, Richard
Lamanna, Nicole
Mato, Anthony
Montillo, Marco
O’Brien, Susan
Dubowy, Ronald
Gu, Lin
Munugalavadla, Veerendra
Robak, Tadeusz
Hillmen, Peter
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA213442-01A1)
Gilead Sciences, Inc Melton Fund Rosenbach Fund
Article History
Received: 1 June 2020
Revised: 25 June 2020
Accepted: 2 July 2020
First Online: 12 July 2020
Compliance with ethical standards
:
: JRB has served as a consultant for Abbvie, Acerta, Astra-Zeneca, BeiGene, Catapult, Dynamo Therapeutics, Genentech/Roche, Gilead, Juno/Celgene, Kite, Loxo, MEI Pharma, Nextcea, Novartis, Octapharma, Pfizer, Pharmacyclics, Sunesis, TG Therapeutics, Verastem; received honoraria from Janssen and Teva; received research funding from Gilead, Loxo, Sun and Verastem; and served on data safety monitoring committees for Morphosys and Invectys. AZ has served as a consultant for JUNO/Celgene, Genentech/Roche, Gilead, BeiGene, Amgen, Pharmacyclics, Janssen, Astra-Zeneca, Novartis/SANDOZ, MEI Pharma; received research support from Genentech/Roche, Gilead, BeiGene, MEI Pharma; and served on scientific advisory boards for the Lymphoma Research Foundation and Adaptive Biotechnologies. RF has served as a consultant for Abbvie, Acerta, Astra-Zeneca, Beigene, Genentech, Janssen, Loxo Oncology, Oncotracker, Pharmacyclics, Sunesis, TG Therapeutics, Verastem Oncology; received speaking fees from Janssen; received research funding from TG Therapeutics and AstraZeneca; and served on the data safety and monitoring board for Incyte. NL has served as a consultant for Abbvie, Astra-Zeneca, Bei-Gene, Celgene, Gilead, Genentech, Juno, Janssen/Pharmacyclics, Octapharma; received research funding from Abbvie, Astra-Zeneca, BeiGene, Genentech, Juno, Infinity/Verastem, Octapharma, Oncternal, Ming Therapeutics, TG Therapeutics; and served on advisory boards for Abbvie, Astra Zeneca, BeiGene, Celgene, Gilead, Genentech, Juno, Janssen/Pharmacyclics, and Octapharma. ARM holds a consultancy role for TG Therapeutics, Abbvie, Pharmacyclics, Johnson & Johnson, Regeneron, Astra-Zeneca, Genentech, Loxo, Celgene, Sunesis, Adaptive; received research funding from TG Therapeutics, Abbvie, Pharmacyclics, Johnson & Johnson, Regeneron, Genentech, Loxo, Portola, DTRM, Adaptive, Acerta; and served on the data safety monitoring board for TG Therapeutics and Celgene. MM has received honoraria from Abbvie, Gilead, Janssen, Roche; and served on the advisory board for Abbvie, Acerta/Astra-Zeneca, Gilead, Janssen, Roche, and Verastem. SO has served as a consultant for Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc., Vaniam Group LLC, Abbvie, Alexion, Verastem, Eisai, Juno Therapeutics, Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunsesis; and received research support from Kite, Regeneron, Acerta, Gilead, Pharmacyclics, TG Therapeutics, Pfizer, and Sunesis. RD has served as a consultant for Acerta Pharma; was formerly employed by Gilead; is currently employed by Juno Therapeutics (BMS); and owns stock in Gilead Sciences, Bristol-Myers-Squibb, and Forty Seven. LG has served as an independent contractor for Gilead; and is employed by Gilead. VM worked as an employee of Gilead while the work was conducted; is currently employed with Acerta Pharma; and owns stock in Astra-Zeneca and Gilead Sciences. TR has served in an advisory role for Gilead; received honoraria from Gilead; and received research funding from Gilead. PH has received honoraria from Janssen and Abbvie; received research funding from Janssen, Abbvie, Pharmacyclics, Gilead, Roche, Apellis; and has served on an advisory board for Janssen, Abbvie, and Alexion.